These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27009878)

  • 21. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancer.
    Liu CL; Chen SF; Wu MZ; Jao SW; Lin YS; Yang CY; Lee TY; Wen LW; Lan GL; Nieh S
    Oncotarget; 2016 Mar; 7(12):14279-90. PubMed ID: 26872057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ginsenoside Rg3 sensitizes hypoxic lung cancer cells to cisplatin via blocking of NF-κB mediated epithelial-mesenchymal transition and stemness.
    Wang J; Tian L; Khan MN; Zhang L; Chen Q; Zhao Y; Yan Q; Fu L; Liu J
    Cancer Lett; 2018 Feb; 415():73-85. PubMed ID: 29199005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
    Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway.
    Ren T; Shan J; Qing Y; Qian C; Li Q; Lu G; Li M; Li C; Peng Y; Luo H; Zhang S; Zhang W; Wang D; Zhou SF
    Drug Des Devel Ther; 2014; 8():2517-29. PubMed ID: 25548514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-324-5p upregulation potentiates resistance to cisplatin by targeting FBXO11 signalling in non-small cell lung cancer cells.
    Ba Z; Zhou Y; Yang Z; Xu J; Zhang X
    J Biochem; 2019 Dec; 166(6):517-527. PubMed ID: 31778188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisplatin treatment induced interleukin 6 and 8 production alters lung adenocarcinoma cell migration in an oncogenic mutation dependent manner.
    Kiss E; Abdelwahab EHMM; Steib A; Papp E; Torok Z; Jakab L; Smuk G; Sarosi V; Pongracz JE
    Respir Res; 2020 May; 21(1):120. PubMed ID: 32434541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Huaier suppresses cisplatin resistance in non-small cell lung cancer by inhibiting the JNK/JUN/IL-8 signaling pathway.
    Jin H; Liu C; Liu X; Wang H; Zhang Y; Liu Y; Li J; Yu Z; Liu HX
    J Ethnopharmacol; 2024 Jan; 319(Pt 2):117270. PubMed ID: 37832810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells.
    Sun Y; Zheng S; Torossian A; Speirs CK; Schleicher S; Giacalone NJ; Carbone DP; Zhao Z; Lu B
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e563-72. PubMed ID: 22197230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC.
    MacDonagh L; Gray SG; Breen E; Cuffe S; Finn SP; O'Byrne KJ; Barr MP
    Cancer Lett; 2018 Aug; 428():117-126. PubMed ID: 29653268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin.
    Shin DH; Choi YJ; Park JW
    Cancer Res; 2014 Jan; 74(1):298-308. PubMed ID: 24240701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sulforaphane Inhibits the Acquisition of Tobacco Smoke-Induced Lung Cancer Stem Cell-Like Properties
    Xie C; Zhu J; Jiang Y; Chen J; Wang X; Geng S; Wu J; Zhong C; Li X; Meng Z
    Theranostics; 2019; 9(16):4827-4840. PubMed ID: 31367260
    [No Abstract]   [Full Text] [Related]  

  • 33. Yi-qi-yang-yin-tian-sui-fang enhances cisplatin-induced tumor eradication and inhibits interleukin-7 reduction in non-small cell lung cancer.
    Ke B; Wu X; Yang Q; Huang Y; Wang F; Gong Y; Liu J; Shi L
    Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31138762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel pathways involved in cisplatin resistance identified by a proteomics approach in non-small-cell lung cancer cells.
    Milone MR; Lombardi R; Roca MS; Bruzzese F; Addi L; Pucci B; Budillon A
    J Cell Physiol; 2019 Jun; 234(6):9077-9092. PubMed ID: 30362533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer.
    Xiao L; Lan X; Shi X; Zhao K; Wang D; Wang X; Li F; Huang H; Liu J
    Cell Death Dis; 2017 May; 8(5):e2803. PubMed ID: 28518145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.
    Kang HN; Kim SH; Yun MR; Kim HR; Lim SM; Kim MS; Hong KW; Kim SM; Kim H; Pyo KH; Park HJ; Han JY; Youn HA; Chang KH; Cho BC
    Lung Cancer; 2016 May; 95():57-64. PubMed ID: 27040853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro.
    Wang WJ; Sui H; Qi C; Li Q; Zhang J; Wu SF; Mei MZ; Lu YY; Wan YT; Chang H; Guo PT
    Oncol Rep; 2016 Jul; 36(1):428-40. PubMed ID: 27221674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NFκB and TNFα as individual key molecules associated with the cisplatin-resistance and radioresistance of lung cancer.
    Zhu R; Xue X; Shen M; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
    Exp Cell Res; 2019 Jan; 374(1):181-188. PubMed ID: 30508513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer.
    Shoji T; Kikuchi E; Kikuchi J; Takashima Y; Furuta M; Takahashi H; Tsuji K; Maeda M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
    Cancer Chemother Pharmacol; 2020 May; 85(5):843-853. PubMed ID: 32232513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.